Results 241 to 250 of about 5,351,550 (365)

Minimal Residual Disease as an Early Endpoint for Accelerated Drug Approval in Myeloma: A Roadmap. [PDF]

Blood Cancer Discov
Landgren O, Devlin SM.
europepmc   +1 more source

An estimate of rate of deviation from NCCN guideline recommendations for central nervous system imaging in trials forming basis for drug approval in first line advanced non-small cell lung cancer (NSCLC). [PDF]

BMC Cancer, 2022
Sharp J, Prasad V.
europepmc   +1 more source

Bioengineering facets of the tumor microenvironment in 3D tumor models: insights into cellular, biophysical and biochemical interactions

FEBS Open Bio, EarlyView.
The tumor microenvironment is a dynamic, multifaceted complex system of interdependent cellular, biochemical, and biophysical components. Three‐dimensional in vitro models of the tumor microenvironment enable a better understanding of these interactions and their impact on cancer progression and therapeutic resistance.
Salma T. Rafik, Deniz Bakkalci, Alexander J. MacRobert, Umber Cheema   +3 more
wiley   +1 more source

Critical insights into the evolving drug-approval process in China. [PDF]

Cancer
Nikanjam M, Kurzrock R.
europepmc   +1 more source

New Drug and Biologics Approvals in 2019: A Systematic Analysis of Patient Experience Data in FDA Drug Approval Packages and Product Labels. [PDF]

Ther Innov Regul Sci, 2021
Schultz-Knudsen K, Sabaliauskaite U, Hellsten J, Lassen AB, Morant AV.   +4 more
europepmc   +1 more source

U.S. Food and Drug Administration Approval: Panitumumab for Epidermal Growth Factor Receptor–Expressing Metastatic Colorectal Carcinoma with Progression Following Fluoropyrimidine-, Oxaliplatin-, and Irinotecan-Containing Chemotherapy Regimens [PDF]

, 2008
Ruthann M. Giusti, Kaushikkumar A. Shastri, Anne M. Pilaro, Chana Fuchs, Ruth Cordoba-Rodriguez, Kallappa M. Koti, Mark D. Rothmann, Angela Men, Hong Zhao, Monica Hughes, Patricia Keegan, Karen D. Weiss, Richard Pazdur   +12 more
openalex   +1 more source

Comparative single‐cell transcriptomic profiling of patient‐derived renal carcinoma cells in cellular and animal models of kidney cancer

FEBS Open Bio, EarlyView.
We generated and characterized clear cell renal cell carcinoma models using the patient‐derived RCC243 cell line—including cell culture, orthotopic, and metastatic tumors—via single‐cell RNA‐sequencing for comparisons between models and patient tumor datasets.
Richard Huang, Lynn Kee, Alexander Gont, Jalna Meens, Fraser G. Ferens, Meredith S. Irwin, Laurie Ailles, Scott A. Yuzwa, Claire M. Robinson, Michael Ohh   +9 more
wiley   +1 more source

Targeted Therapies, Novel Antibodies, and Immunotherapies in Advanced Non-Small Cell Lung Cancer: Clinical Evidence and Drug Approval Patterns. [PDF]

Clin Cancer Res
Koban MU, Hartmann M, Amexis G, Franco P, Huggins L, Shah I, Karachaliou N.   +6 more
europepmc   +1 more source

Predictors of orphan drug approval in the European Union [PDF]

, 2008
Harald E. Heemstra, Remco L. de Vrueh, Sonja van Weely, Hans A. Büller, Hubert G. M. Leufkens   +4 more
openalex   +1 more source

METTL3 knockout accelerates hepatocarcinogenesis via inhibiting endoplasmic reticulum stress response

FEBS Open Bio, EarlyView.
Liver‐specific knockout of N6‐methyladenosine (m6A) methyltransferase METTL3 significantly accelerated hepatic tumor initiation under various oncogenic challenges, contrary to the previously reported oncogenic role of METTL3 in liver cancer cell lines or xenograft models. Mechanistically, METTL3 deficiency reduced m6A deposition on Manf transcripts and
Bo Cui, Silin Tu, Haibo Li, Zhancheng Zeng, Ruiqi Xiao, Jing Guo, Xiaoqi Liang, Chang Liu, Lijie Pan, Wenjie Chen, Mian Ge, Xiaofen Zhong, Linsen Ye, Huaxin Chen, Qi Zhang, Yan Xu   +15 more
wiley   +1 more source